Donate Help Contact The AHA Sign In Home
American Heart Association
Circulation
Search: search_blue_button Advanced Search
Published Online
on September 14, 2009

Circulation. 2009
Published online before print September 14, 2009, doi: 10.1161/CIRCULATIONAHA.108.843334
A more recent version of this article appeared on September 29, 2009
This Article
Right arrow Full Text (PDF)
Right arrow CME: Take the course for this article:
Circulation: September 29, 2009, Volume 120, Number 13
Right arrow All Versions of this Article:
120/13/1203    most recent
CIRCULATIONAHA.108.843334v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Rapezzi, C.
Right arrow Articles by Perlini, S.
PubMed
Right arrow PubMed Citation
Right arrow Articles by Rapezzi, C.
Right arrow Articles by Perlini, S.
Right arrowPubmed/NCBI databases
*Substance via MeSH
Medline Plus Health Information
*Amyloidosis
*Cardiomyopathy
Related Collections
Right arrow Myocardial cardiomyopathy disease
Right arrow Electrocardiology
Right arrow Echocardiography
Right arrowRelated Article

Submitted on December 23, 2008
Accepted on July 17, 2009

Systemic Cardiac Amyloidoses. Disease Profiles and Clinical Courses of the 3 Main Types

Claudio Rapezzi MD*, Giampaolo Merlini MD, Candida C. Quarta MD, Letizia Riva MD, Simone Longhi MD, Ornella Leone MD, Fabrizio Salvi MD, Paolo Ciliberti MD, Francesca Pastorelli MD, Elena Biagini MD, Fabio Coccolo MD, Robin M.T. Cooke MA, Letizia Bacchi-Reggiani MSc, MStat, Diego Sangiorgi MStat, Alessandra Ferlini MD, Michele Cavo MD, Elena Zamagni MD, Maria Luisa Fonte MD, Giovanni Palladini MD, Francesco Salinaro MD, Francesco Musca MD, Laura Obici MD, Angelo Branzi MD, and Stefano Perlini MD

From the Institute of Cardiology (C.R., C.C.Q., L.R., S.L., P.C., E.B., F.C., R.M.T.C., L.B.-R., D.S., A.B.), Department of Pathology (O.L.), and Institute of Hematology (M.C., E.Z.), University of Bologna, and S. Orsola-Malpighi Hospital, Bologna; Center for Amyloidosis, Fondazione IRCCS San Matteo and University of Pavia, Pavia (G.M., M.L.F., G.P., F. Salinaro, F.M., L.O., S.P.); Department of Neurology, Bellaria Hospital, Bologna (F. Salvi, F.P.); and Department of Diagnostic and Experimental Medicine, Section of Medical Genetics, University of Ferrara, Ferrara (A.F.), Italy.

* To whom correspondence should be addressed. E-mail: claudio.rapezzi{at}unibo.it.

Background—Most studies of amyloidotic cardiomyopathy consider as a single entity the 3 main systemic cardiac amyloidoses: acquired monoclonal immunoglobulin light-chain (AL); hereditary, mutated transthyretin-related (ATTRm); and wild-type transthyretin-related (ATTRwt). In this study, we compared the diagnostic/clinical profiles of these 3 types of systemic cardiac amyloidosis.

Methods and Results—We conducted a longitudinal study of 233 patients with clear-cut diagnosis by type of cardiac amyloidosis (AL, n=157; ATTRm, n=61; ATTRwt, n=15) at 2 large Italian centers providing coordinated amyloidosis diagnosis/management facilities since 1990. Average age at diagnosis was higher in AL than in ATTRm patients; all ATTRwt patients except 1 were elderly men. At diagnosis, mean left ventricular wall thickness was higher in ATTRwt than in ATTRm and AL. Left ventricular ejection fraction was moderately depressed in ATTRwt but not in AL or ATTRm. ATTRm patients less often displayed low QRS voltage (25% versus 60% in AL; P<0.0001) or low voltage-to-mass ratio (1.1±0.5 versus 0.9±0.5; P<0.0001). AL patients appeared to have greater hemodynamic impairment. On multivariate analysis, ATTRm was a strongly favorable predictor of survival, and ATTRwt predicted freedom from major cardiac events.

Conclusions—AL, ATTRm, and ATTRwt should be considered 3 different cardiac diseases, probably characterized by different pathophysiological substrates and courses. Awareness of the diversity underlying the cardiac amyloidosis label is important on several levels, ranging from disease classification to diagnosis and clinical management.


Key words: amyloid • cardiomyopathy • echocardiography • electrocardiography • myocardium • myocytes, cardiac


Related Article:

Clinical Summaries
Circulation 2009 120: 1165-1167. [Extract] [Full Text]